Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Nordion extends Mo-99 supply deal with Lantheus Medical Imaging through 2015

Nordion : 23 October, 2012  (Company News)
Nordion is extending the company's contract with its primary Medical Isotopes customer, Lantheus Medical Imaging (LMI) for the supply of Molybdenum-99 (Mo-99).


Under the terms of the amended agreement, the contract has been extended for an additional two years through 2015. Nordion expects to supply Mo-99 on a weekly basis to Lantheus Medical Imaging. The multi-year contract reflects specific pricing for each year of the contract. Lantheus is Nordion's single largest customer, purchasing the majority of Nordion's Mo-99.



"Lantheus is a world leader in securing and supplying Mo-99. This multi-year agreement with Nordion underlines our commitment to serving the global nuclear medicine community through a diversified and balanced supply chain for Mo-99," said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging. "We look forward to this continuation of our long-standing relationship with Nordion."



"We are pleased to extend our contract with Lantheus. This agreement provides Nordion with additional clarity of the multi-year demand for our Mo-99," said Steve West, Chief Executive Officer, Nordion. "Both Nordion and Lantheus continue to be important participants in the global supply chain for Mo-99 which is so critical to physicians and patients worldwide."



Medical isotopes are used by physicians to diagnose and treat a number of diseases, including cardiac and neurological conditions, and several types of cancer. Mo-99, and more specifically the derivative medical isotope technetium-99m, is utilised in approximately 80 percent of nuclear medical procedures worldwide.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo